AGM 2024 - QUESTIONS, page-17

Before I give this thread a break until the new year my view for Q&A is to be extremely focused given the limited time made available. Some of the above are not critical IMO and can be asked at the AGM in person after the formal meeting is closed.

1. Commercial deals including feedback from those signing NDA - per posted by TanamiRod above. I note they have changed the narrative to regional deals for MPS and now OA (China). What the hell is happening with the the main game - partnering is our target market (US, EU5)???????? Most critically has the thinking NOW changed to post 002-003 read-out and if so why given all the DMOAD data is now out? If so think about the implications and inherent risk!!!!!!!!!!!
2. Probability of getting dosage back to 2mg/kg x 2 week for Stage 2 - without which its GAME OVER. Forget MPS and all other side hustles as no one appears to care at this stage.

The above are existential to PAR's future and we shouldn't kid ourselves that PAR is anything other than a one man band. Yes governance is a farce but the damage is now done, inclusive of performance rights. So whilst interesting its a side issue that will only be resolved if the above 2 questions are resolved.